ophthalmic

Partner Content
Ophthalmic Drugs 2018
Partner Content

The future of ocular gene editing is here

SMi Group are delighted to welcome the expertise from a senior panel of big pharma and ophthalmic organisations, as well as regulatory bodies, at the 2nd annual Ophthalmic Drugs 2018 conference, ta